You are here

  • Home
  • Archive
  • Volume 52, Issue 10
  • Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines

Article Text

Article menu
Download PDFPDF
Letter
Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines
  1. R F Logan1,
  2. T P van Staa2
  1. 1Clinical Epidemiology, University Hospital, Nottingham, UK
  2. 2Procter & Gamble Pharmaceuticals, Egham, UK
  1. Correspondence to:
    Professor RFA Logan, Division of Public Health and Epidemiology, School of Community Health Sciences, University of Nottingham Medical School, Nottingham NG7 2UH, UK;
    Richard.Logan{at}nottingham.ac.uk

https://doi.org/10.1136/gut.52.10.1530

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We were interested to read the report by Ransford and Langman of their analysis of yellow card reports of suspected adverse drugs reactions for sulphasalazine and mesalazine (

    ). These reports, submitted to the Committee on Safety of Medicines, may provide useful flags to signal unrecognised hazards of drugs. However, as adverse reactions are not always recognised or reported to the regulatory authorities by physicians, these reports usually underestimate the frequency of any adverse drug reaction. Of greater importance, underreporting is usually not random but selective, which may introduce serious bias when comparing different drugs.1 Various examples have been described previously of drugs that showed substantive differences in reporting rates, which were not substantiated after further research.1 For this reason, it is recommended that, once there is a signal for a suspected adverse drug reaction, other sources of data are investigated.2

    We recently initiated a study to quantify the risk of renal toxicity in patients taking aminosalicylate (5-ASA) drugs in the UK. The General Practice Research Database (GPRD) was used for this study, …

    View Full Text